Zoey Becker

After last quarter presenting three factors necessary for a more successful launch of hemophilia A gene therapy Roctavian, BioMarin has now added a divestiture to the list of potential paths for the struggling medicine.

While an ongoing production expansion push for Eli Lilly's popular tirezeptide-based medicines Mounjaro and Zepbound should help out with perpetual supply strains later this year, the expected gains are no match for rampant demand.

Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK and its leading Arexvy shot aren’t sweating.

Novo Nordisk is facing fierce competition from Eli Lilly's obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug.

Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte's approved Opzelura.

Zydus Lifesciences recently received its second Form 483 reprimand from the FDA within the span of one month.

After a 2023 approval from the FDA, Krystal Biotech has collected more than $95 million from its launch of Vyjuvek, the first treatment for the rare skin disease dystrophic epidermolysis bullo

After bringing slow-release schizophrenia drug Uzedy to market last year, Teva and France's MedinCell are using the same playbook for a similar candidate.

As U.S. drug shortages run rampant, lawmakers are getting creative with their attempts to ease the situation.

In response to rapidly declining profits and the downfall of ADHD drug Vyvanse, Takeda is planning to throw 140 billion Japanese yen ($899 million) toward a company-wide restructuring campaign.